INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Lifestyle Strategies for Symptom Relief and Disease Progression Control in Interstitial Lung Disease: A Comprehensive Review

Abushan Khan*, Dr. Kaushal Kumar

Department of Pharmacy, MJP Rohilkhand University, Bareilly, UP, IN.

ARTICLE INFO

Published: 03 Sept. 2025
Keywords:
Interstitial lung disease, lifestyle medicine, pulmonary rehabilitation, nutrition, environmental health, patient education
DOI:
10.5281/zenodo.17046299

ABSTRACT

Background: Interstitial lung diseases (ILD) represent a heterogeneous group of pulmonary disorders characterized by progressive fibrosis and inflammation of the lung parenchyma. While pharmacological interventions remain the cornerstone of treatment, lifestyle modifications play an increasingly recognized role in symptom management and potentially slowing disease progression. Objective: This review synthesizes current evidence on lifestyle strategies that can improve quality of life, reduce symptom burden, and potentially influence disease trajectory in ILD patients. Methods: A comprehensive literature review was conducted examining peer-reviewed studies, clinical guidelines, and expert consensus statements published between 2015 and 2025 focusing on non-pharmacological lifestyle interventions in ILD management. Results: Key lifestyle strategies with evidence-based support include pulmonary rehabilitation programs, nutritional optimization, smoking cessation, environmental exposure avoidance, sleep hygiene, stress management, and vaccination protocols. These interventions demonstrate potential for symptom improvement, functional capacity enhancement, and quality of life benefits. Conclusions: A multifaceted approach incorporating evidence-based lifestyle modifications alongside standard medical care offers the best prospects for comprehensive ILD management. Further research is needed to establish optimal implementation protocols and long-term outcomes.

INTRODUCTION

Interstitial lung diseases encompass over 200 distinct conditions affecting the lung interstitium, with idiopathic pulmonary fibrosis (IPF) being the most common and severe form.[1] These progressive conditions are characterized by varying degrees of inflammation and fibrosis, leading to impaired gas exchange, reduced exercise capacity, and ultimately respiratory failure.[2] The heterogeneous nature of ILD, combined with limited therapeutic options and

***Corresponding Author:** Abushan Khan
Address: *Department of Pharmacy, MJP Rohilkhand University, Bareilly, UP, IN.*
Email ✉: akabushan@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

generally poor prognosis, necessitates a comprehensive approach that extends beyond pharmacological interventions.[3]. The concept of lifestyle medicine has gained significant traction in chronic disease management, recognizing that modifiable behavioral and environmental factors can substantially influence disease outcomes.[4] In the context of ILD, lifestyle strategies serve multiple purposes: symptom palliation, functional preservation, quality of life enhancement, and potentially disease modification.[5] This review examines the current evidence base for lifestyle interventions in ILD management, providing a framework for clinicians and patients to implement evidence-based non-pharmacological strategies.[6]. The rationale for lifestyle intervention in ILD is multifaceted. First, the progressive nature of these diseases often leads to deconditioning, nutritional deficiencies, and psychological distress, creating a cycle of functional decline.[7] Second, many ILD patients have comorbidities that benefit from lifestyle modification, including cardiovascular disease, diabetes, and osteoporosis. Third, emerging evidence suggests that certain lifestyle factors may influence inflammatory pathways and fibrotic processes, potentially impacting disease progression.[8]

2. Pulmonary Rehabilitation

2.1 Evidence Base and Mechanisms

Pulmonary rehabilitation represents the most extensively studied lifestyle intervention in ILD management. Multiple randomized controlled trials and systematic reviews have demonstrated consistent benefits across various ILD subtypes.[9] The physiological rationale centers on breaking the dyspnea-deconditioning cycle while optimizing respiratory muscle function and peripheral muscle strength.[10]

Exercise training in ILD patients improves several key outcomes: exercise capacity measured by six-minute walk distance, muscle strength, dyspnea perception, and health-related quality of life.[11] The mechanisms underlying these improvements include enhanced oxygen utilization efficiency, improved cardiac output, strengthened respiratory muscles, and reduced anxiety associated with exertion.[12]

2.2 Program Components

Comprehensive pulmonary rehabilitation programs for ILD patients typically include:

Aerobic Exercise Training: Progressive endurance training using treadmill, cycling, or walking protocols. Initial intensities are typically set at 60-80% of peak work rate, with careful monitoring of oxygen saturation and symptoms.[13] Session duration progresses from 15-20 minutes initially to 30-45 minutes over 6-12 weeks.[14]

Resistance Training: Strength training targeting major muscle groups, particularly those involved in breathing and ambulation.[15] Programs typically include 2-3 sets of 8-12 repetitions at 60-80% of one-repetition maximum, performed 2-3 times weekly.[16]

Respiratory Muscle Training: Specific exercises targeting inspiratory and expiratory muscles using threshold devices or breathing techniques. Inspiratory muscle training typically involves 30% of maximal inspiratory pressure for 15-30 minutes daily.[17]

Education Component: Disease-specific education covering pathophysiology, symptom management, medication adherence, energy conservation techniques, and advance directive planning.[18]

2.3 Implementation Considerations

Successful implementation requires careful patient selection and monitoring. Candidates should have stable disease without recent exacerbations, adequate oxygen saturation during activity (typically >88%), and absence of significant cardiac comorbidities.[19] Oxygen supplementation during exercise is often necessary and should be titrated to maintain saturation above 88%.[20]

Safety protocols include continuous pulse oximetry monitoring, blood pressure assessment, and symptom evaluation using validated dyspnea scales.[21] Exercise sessions should be terminated if oxygen saturation falls below 85% despite supplementation, systolic blood pressure exceeds 200 mmHg, or patients experience severe dyspnea or chest pain.[22]

3. Nutritional Optimization

3.1 Nutritional Challenges in ILD

ILD patients face multiple nutritional challenges that can significantly impact disease outcomes. Progressive respiratory impairment increases metabolic demands while simultaneously reducing appetite and food intake capacity.[23] Chronic hypoxemia and inflammation contribute to muscle wasting and weight loss. Additionally, many ILD patients develop gastroesophageal reflux disease, which may exacerbate pulmonary symptoms and further compromise nutritional status.[24]

Malnutrition in ILD is associated with increased mortality, reduced exercise capacity, impaired immune function, and decreased quality of life.[25] Studies indicate that 20–35% of ILD patients are undernourished, with a higher prevalence at advanced disease stages.[26]

3.2 Nutritional Assessment and Monitoring

Comprehensive nutritional assessment should include anthropometric measurements, biochemical markers, dietary intake evaluation, and functional assessments.[27] Key parameters include body mass index, unintentional weight loss, albumin and prealbumin levels, vitamin D status, and muscle mass evaluation using bioelectrical impedance or DEXA scanning.[28]

Regular monitoring is essential, as nutritional status can deteriorate rapidly during disease exacerbations or with treatment side effects.[29] Monthly weight assessments and quarterly comprehensive nutritional evaluations are recommended for stable patients, with more frequent monitoring during acute episodes.[30]

3.3 Nutritional Interventions

Caloric and Protein Adequacy: ILD patients often require 25–35% above normal caloric intake due to increased work of breathing.[31] Protein requirements are raised to 1.2–1.5 g/kg body weight to counteract muscle catabolism. Small, frequent meals (6-8 per day) are better tolerated than traditional three-meal patterns.[32]

Micronutrient Optimization: Special attention should be paid to vitamin D supplementation, given the high prevalence of deficiency and potential anti-inflammatory effects.[33] Target 25-hydroxyvitamin D levels should exceed 30 ng/mL. Other important micronutrients include vitamin C for antioxidant effects, B-complex vitamins for energy metabolism, and minerals such as magnesium and selenium.[34]

Anti-inflammatory Nutrition: Dietary patterns emphasizing anti-inflammatory foods may provide additional benefits. The Mediterranean diet pattern, rich in omega-3 fatty acids, polyphenols, and antioxidants, shows promise in reducing inflammatory markers. Specific foods to emphasize include fatty fish, leafy greens, berries, nuts, and olive oil.[35]

Hydration Management: Adequate hydration supports mucus clearance and prevents complications. However, fluid restriction may be necessary in patients with cor pulmonale or heart failure. Individual assessment is crucial to balance hydration needs with cardiac status.[36]

4. Environmental Exposure Management

4.1 Occupational and Environmental Triggers

Environmental exposure management is crucial for preventing disease progression and reducing symptom exacerbations in ILD patients. Many ILD cases have identifiable environmental triggers, including occupational dusts, chemicals, molds, and air pollutants. Even in idiopathic cases, ongoing exposures may contribute to disease progression.[37] Commonly problematic exposures include silica dust, asbestos fibers, metal dust, organic antigens from birds or moldy environments, and various industrial chemicals. Indoor air quality issues such as mold, dust mites, and volatile organic compounds can also trigger symptoms.[38]

4.2 Assessment and Identification

Comprehensive environmental history-taking is essential for all ILD patients. This includes detailed occupational history spanning the entire career, hobby and recreational exposures, home environment assessment, and identification of potential ongoing exposures. Environmental questionnaires and specialist consultation may be necessary for complex cases.[39]

Home environment assessment should evaluate heating and cooling systems, humidity levels, presence of mold or water damage, pet exposures, and use of chemical products. Indoor air quality testing may be indicated in suspected cases of ongoing exposure.[40]

4.3 Mitigation Strategies

Occupational Modifications: Complete cessation of identified occupational exposures is paramount. This may require job modification, workplace engineering controls, or career change in severe cases. Personal protective equipment, while advantageous, is generally insufficient as sole protection in sensitized individuals.[41]

Home Environment Optimization: Measures include maintaining indoor humidity between 30 and 50%, regular HVAC filter changes, mold remediation, when necessary, reduction of dust-collecting items, and use of HEPA filtration systems. Chemical exposure reduction involves switching to fragrance-free and low-VOC products.[42]

Air Quality Management: Monitoring local air quality indices and limiting outdoor activities during high pollution days. Indoor air purifiers with HEPA filtration can be beneficial, particularly in urban environments or during wildfire seasons.[43]

5. Smoking Cessation

5.1 Impact of Smoking on ILD

Smoking cessation is universally recommended for ILD patients, as tobacco use accelerates disease progression and increases mortality risk. Smoking contributes to ongoing lung inflammation, impairs mucociliary clearance, and increases susceptibility to respiratory infections. Additionally, smoking significantly increases lung cancer risk, which is already elevated in many ILD patients.[44]

The relationship between smoking and ILD is complex, with some conditions like desquamative interstitial pneumonia being directly caused by smoking, while others like IPF show accelerated progression in current smokers. Even former smokers benefit from comprehensive smoking cessation support to prevent relapse.[45]

5.2 Cessation Strategies

Behavioural Interventions: Comprehensive counseling addressing triggers, coping strategies, and lifestyle modifications. Motivational interviewing techniques are particularly effective in ILD patients who may feel overwhelmed by their diagnosis.[46]

Pharmacological Support: Nicotine replacement therapy, bupropion, or varenicline may be appropriate depending on individual circumstances and contraindications. Careful consideration of drug interactions with ILD medications is necessary.[47]

Support Systems: Integration with smoking cessation programs, support groups, and digital health platforms can improve success rates. Family involvement and peer support are particularly valuable.[48]

5.3 Addressing Barriers

Common barriers to smoking cessation in ILD patients include fear of weight gain during a period of potential nutritional vulnerability, concern about losing a coping mechanism for stress, and nihilistic attitudes about prognosis. Addressing these concerns proactively and providing alternative coping strategies is essential for success.[49]

6. Sleep Optimization

6.1 Sleep disorders in ILD

Sleep disturbances are common in ILD patients, affecting up to 80% of individuals with various forms of interstitial pneumonia. Sleep-disordered breathing, including obstructive sleep apnea and nocturnal hypoventilation, occurs frequently and may contribute to disease progression through intermittent hypoxemia and inflammatory cascades.[50]

Nocturnal cough, dyspnea, medication side effects, and anxiety about prognosis further compromise sleep quality. Poor sleep quality correlates with increased daytime fatigue, reduced exercise capacity, and impaired quality of life.[51]

6.2 Assessment and Diagnosis

Sleep assessment should include standardized questionnaires such as the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale. Overnight pulse oximetry can identify nocturnal desaturation, while formal sleep studies may be indicated for suspected sleep-disordered breathing.[52] Clinical indicators for sleep study evaluation include witnessed apneas, morning headaches, excessive daytime sleepiness, and nocturnal oxygen desaturation. The high prevalence of sleep disorders in ILD patients supports a low threshold for formal evaluation.[53]

6.3 Sleep Optimization Strategies

Sleep Hygiene: Standard sleep hygiene measures including a consistent sleep schedule, an optimized sleep environment (dark, cool, and quiet), limited screen time before bed, and avoidance of stimulants in the evening.[54]

Positioning: Elevation of the head of the bed can improve both sleep quality and gastroesophageal reflux symptoms. Side sleeping may be preferable for some patients to optimize ventilation-perfusion matching.

Oxygen Therapy: Nocturnal oxygen supplementation may be necessary for patients with significant desaturation. Proper equipment selection and patient education are crucial for compliance and effectiveness.

Treatment of Sleep Disorders: CPAP therapy for obstructive sleep apnea, with careful attention to mask fitting and pressure titration. Some patients may require bilevel positive airway pressure for nocturnal hypoventilation.[55]

7. Stress Management and Psychological Support

7.1 Psychological Impact of ILD

ILD diagnosis and progression create significant psychological distress, with anxiety and depression rates exceeding those in the general population. Disease uncertainty, progressive functional decline, and limited treatment options contribute to psychological burden. Additionally, symptoms such as dyspnea can trigger anxiety, creating a vicious cycle of symptom exacerbation.[56] The impact extends to caregivers and family members, who often experience their own psychological distress while providing support. Addressing psychological needs is integral to comprehensive ILD care and may influence both symptom perception and disease outcomes.

7.2 Assessment and Screening

Regular screening for anxiety and depression using validated instruments such as the Hospital Anxiety and Depression Scale or Patient Health Questionnaire-9 should be incorporated into routine care. Assessment should also evaluate coping mechanisms, social support systems, and spiritual needs.[57]

7.3 Intervention Strategies

Cognitive-Behavioural Therapy: CBT techniques help patients develop coping skills, challenge catastrophic thinking, and manage anxiety related to breathlessness. Pulmonary-specific CBT programs show particular promise in ILD populations.[58]

Mindfulness and Relaxation: Mindfulness-based stress reduction, progressive muscle relaxation, and breathing techniques can reduce anxiety and improve quality of life. These approaches are particularly valuable, as they can be practiced independently and integrated into daily routines.[59]

Support Groups: ILD-specific support groups, whether in-person or virtual, provide peer support, emotional support, and practical advice from others with shared experiences.[60]

Spiritual Care: Addressing spiritual needs and existential concerns, particularly important given the progressive nature of many ILD conditions. Chaplaincy services and spiritual counselling may be valuable components of comprehensive care.[61]

8. Infection Prevention

8.1 Infection Risk in ILD

ILD patients face increased susceptibility to respiratory infections due to impaired mucociliary clearance, compromised lung architecture, and often immunosuppressive treatments. Respiratory infections can trigger acute exacerbations, accelerate disease progression, and increase mortality risk.[62]. The risk is particularly elevated in patients receiving immunosuppressive therapy, those with advanced disease, and individuals with comorbid conditions such as diabetes or cardiac disease.[63]

8.2 Vaccination Strategies

Routine Immunizations: Annual influenza vaccination is strongly recommended for all ILD patients. Pneumococcal vaccination with both PCV13 and PPSV23 should be administered according to current guidelines, with consideration

for earlier revaccination in immunocompromised patients.[64]

COVID-19 Prevention: COVID-19 vaccination is crucial given the increased risk of severe outcomes in ILD patients. Additional booster doses may be recommended based on evolving guidelines and individual risk factors.[65]

Other Vaccines: Consider vaccination against respiratory syncytial virus (RSV) in appropriate candidates, and ensure routine vaccines such as tetanus-diphtheria-pertussis are current.[66]

8.3 General Infection Prevention

Hand Hygiene: Rigorous hand hygiene practices, including proper technique and frequency, are fundamental to infection prevention.

Respiratory Etiquette: Covering coughs and sneezes, avoiding close contact with ill individuals, and wearing masks in high-risk settings.[67]

Environmental Precautions: Avoiding crowded spaces during peak respiratory illness seasons, maintaining satisfactory indoor air quality, and prompt treatment of minor respiratory symptoms.[68]

9. Medication Adherence and Management

9.1 Complexity of ILD Pharmacotherapy

ILD patients often require complex medication regimens, including antifibrotic agents, immunosuppressants, supplemental oxygen, and treatments for comorbid conditions. Medication adherence challenges include side effect burden, complex dosing schedules, high costs, and patient concerns about long-term effects.

Poor adherence can lead to disease progression, increased healthcare utilization, and reduced quality of life. Identifying and addressing barriers to adherence is crucial for optimal outcomes.[69]

9.2 Adherence Enhancement Strategies

Patient Education: Comprehensive education about medication mechanisms, expected benefits, potential side effects, and importance of adherence. Written materials and digital resources can reinforce verbal counseling.[70]

Simplified Regimens: Working with healthcare providers to simplify dosing schedules when possible, using combination medications, and coordinating timing with daily routines.

Side Effect Management: Proactive identification and management of medication side effects, with clear protocols for when to contact healthcare providers.

Support Systems: Involving family members or caregivers in medication management, utilizing pill organizers and reminder systems, and considering pharmacy-based adherence programs.[71]

10. Quality of Life and Functional Optimization

10.1 Energy Conservation Techniques

ILD patients benefit significantly from energy conservation strategies that help maximize function while minimizing dyspnea and fatigue. These techniques involve reorganizing daily activities, pacing strategies, and environmental modifications to reduce energy expenditure.[72]

Key principles include planning activities during peak energy periods, breaking large tasks into smaller components, using assistive devices when appropriate, and organizing living spaces to minimize unnecessary movement.[73]

10.2 Assistive Technologies

Mobility Aids: Walking aids such as rollators with oxygen tank holders can improve mobility and confidence. Wheelchair use for longer distances may preserve energy for more important activities.

Home Modifications: Environmental modifications, including grab bars, raised toilet seats, shower chairs, and rearranging furniture to create clear pathways, can improve safety and reduce energy expenditure.[74]

Oxygen Equipment: Portable oxygen concentrators and lightweight delivery systems can maintain independence and quality of life. Proper equipment selection based on individual needs and lifestyle is crucial.[75]

10.3: Social and Recreational Activities

Maintaining social connections and meaningful activities is crucial for psychological well-being. Strategies include modifying favorite activities rather than abandoning them, exploring new interests that are less physically demanding, and utilizing technology to maintain social connections when mobility is limited.[76]

11. Integration of Lifestyle Strategies

11.1 Multidisciplinary Approach

Optimal implementation of lifestyle strategies requires coordinated multidisciplinary care involving pulmonologists, respiratory therapists, nutritionists, social workers, pharmacists, and other specialists as needed. Regular team communication ensures consistent messaging and coordinated interventions.[77]

11.2 Patient-Cantered Care Planning

Lifestyle interventions should be tailored to individual patient preferences, values, and circumstances. Shared decision-making processes help prioritize interventions based on patient goals and likelihood of adherence.

11.3 Monitoring and Adjustment

Regular assessment of intervention effectiveness using both objective measures (exercise capacity, nutritional markers, sleep quality) and subjective outcomes (quality of life scores, symptom burden) allows for ongoing optimization of the lifestyle intervention plan.[78]

12. Future Directions and Research Needs

12.1 Emerging Evidence

Research continues to evolve regarding optimal lifestyle interventions in ILD. Areas of active investigation include home-based pulmonary rehabilitation programs, telehealth-delivered interventions, novel nutritional strategies, and personalized exercise prescriptions based on individual disease characteristics.[79]

12.2 Technology Integration

Digital health technologies, including wearable devices, smartphone applications, and remote monitoring systems, offer promising opportunities to enhance lifestyle intervention delivery and monitoring. These tools may improve adherence, provide real-time feedback, and enable more personalized interventions.[80]

12.3 Research Priorities

Key research needs include long-term outcome studies of lifestyle interventions, optimal timing and sequencing of interventions, cost-effectiveness analyses, and identification of patient subgroups most likely to benefit from specific interventions.[81]

13. CONCLUSIONS

Lifestyle strategies represent a crucial component of comprehensive ILD management, offering evidence-based approaches to improve symptoms, enhance quality of life, and potentially influence disease progression. The complexity of these interventions requires coordinated implementation and ongoing optimization based on individual patient needs and circumstances. Key evidence-supported interventions include structured pulmonary rehabilitation programs, nutritional optimization with attention to caloric adequacy and anti-inflammatory patterns, comprehensive environmental exposure management, smoking cessation support, sleep optimization strategies, psychological support and stress management, infection prevention protocols, and medication adherence enhancement. Success in implementing lifestyle strategies depends on patient engagement, multidisciplinary team coordination, and individualized approaches that consider patient preferences, values, and practical circumstances. Regular monitoring and adjustment of interventions ensure optimal outcomes and patient satisfaction. As our understanding of ILD pathophysiology continues to evolve, lifestyle interventions may play an increasingly important role in disease management. The integration of digital health technologies and personalized medicine approaches holds promise for enhancing the effectiveness and accessibility of lifestyle-based interventions. Healthcare providers caring for ILD patients should prioritize lifestyle counselling and support as an integral component of care, recognizing that these interventions can significantly impact patient outcomes and quality of life. Continued research and clinical experience will further refine our approach to lifestyle medicine in ILD management.

REFERENCES

1. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. (2017) 3:1–19. doi: 10.1038/nrdp.2017.74
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. (2011) 183:788– 824. doi: 10.1164/rccm.2009-040GL
3. Travis WD, Costabel U, Hansell DM, King Jr TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Societystatement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. (2013) 188:733–48. doi: 10.1164/rccm.201308-1483ST
4. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2018) 198:e44–68. doi: 10.1164/rccm.201807-1255ST
5. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2022) 205:e18–47. doi: 10.1164/rccm.202202-0399ST
6. Travis WD, King TE, Bateman ED, Lynch DA, Capron F, Center D, et al. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care

Med. (2002) 165:277–304. doi: 10.1164/ajrccm.165.2.ats01

7. Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2071–82. doi: 10.1056/NEJMoa1402584
8. Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Medicine. (2020) 20:3. doi: 10.1186/s12890-019-1030-4
9. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. (2022) 400:769–86. doi: 10.1016/S0140-6736(22)01052-2
10. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. (2020) 383:958–68. doi: 10.1056/NEJMra2005230
11. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2020) 202:e36–69. doi: 10.1164/rccm.202005-2032ST
12. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2014) 189:e15–62. doi: 10.1164/rccm.201402-0373ST
13. Raghu G, Ley B, Brown KK, Cottin V, Gibson KF, Kaner RJ, et al. Risk factors for disease progression in idiopathic pulmonary fibrosis. Thorax. (2020) 75:78–80. doi: 10.1136/thoraxjnl-2019-213620
14. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. (2014) 44:1428–46. doi: 10.1183/09031936.00150314
15. Méthot DB, Leblanc É, Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. (2019) 155:33–43. doi: 10.1016/j.chest.2018.07.038
16. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. (2012) 366:1968–77. doi: 10.1056/NEJMoa1113354
17. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. (2011) 377:1760–9. doi: 10.1016/S0140-6736(11)60405-4
18. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. (2011) 378:1949–61. doi: 10.1016/S0140-6736(11)60052-4
19. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2083–92. doi: 10.1056/NEJMoa1402582
20. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. (2019) 28:180100. doi: 10.1183/16000617.0100-2018
21. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology. (2016) 21:245–58. doi: 10.1111/resp.12588
22. Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a

sow's ear. Thorax. (2013) 68:309–10. doi: 10.1136/thoraxjnl-2012-202640

23. Antoniou K, Margaritopoulos G, Economidou F, Siafakas N. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. (2009) 33:882–96. doi: 10.1183/09031936.00152607
24. Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. (2018) 27:180076. doi: 10.1183/16000617.0076-2018
25. Paolo S, Philippe B, Giulio R, Nicola S, Vincent C. Drug-induced interstitial lung disease. Eur Respir J. (2022) 60:2102776. doi: 10.1183/13993003.02776-2021
26. Kawano-Dourado L, Glassberg MK, Assayag D, Borie R, Johannson KA. Sex and gender in interstitial lung diseases. Eur Respir Rev. (2021) 30:210105. doi: 10.1183/16000617.0105-2021
27. Torre O, Elia D, Caminati A, Harari S. New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis. Eur Respir Rev. (2017) 26:170042. doi: 10.1183/16000617.0042-2017
28. Spagnolo P, Tzouvelekis A, Bonella F. The management of patients with idiopathic pulmonary fibrosis. Front Med. (2018) 5:148. doi: 10.3389/fmed.2018.00148
29. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. (1999) 16:149–73.Besnier E. Lupus pernio de la face. Ann Dermatol Syph. (1889) 10:333–6.
30. Ahmed MI, Fox R, Shinkins B, Sutton S, Tziaferi V, Gaillard EA. Continuous glucose monitoring systems for the diagnosis of cystic fibrosis-related diabetes. Cochrane Database Syst Rev. (2018)2018:CD012953. doi: 10.1002/14651858.CD01 2953
31. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. (2007) 357:2153–65. doi: 10.1056/NEJMra071714
32. Ishihara M, Ohno S, Ishida T, Ando H, Naruse T, Nose Y, et al. Molecular genetic studies of HLA class II alleles in sarcoidosis. Tissue Antigens. (1994) 43:238– doi: 10.1111/j.1399-0039.1994.tb02331.x
33. Judson MA, Preston S, Hu K, Zhang R, Jou S, Modi A, et al. Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. Respir Med. (2019) 152:14–9. doi: 10.1016/j.rmed.2019.03.012
34. Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. (2017) 24:59–65. doi: 10.1097/MOH.0000000000000301
35. Sreeja C, Priyadarshini A. Premika, Nachiammai N. Sarcoidosis - a review article. J Oral Maxillofac Pathol. (2022) 26:242–53. doi: 10.4103/jomfp.jomfp_373_21
36. Hena KM. Sarcoidosis epidemiology: race matters. Front Immunol. (2020) 11:537382. doi: 10.3389/fimmu.2020.537382
37. Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. (2020) 201:e26–doi: 10.1164/rccm.202002-0251ST
38. Sharp M, Psoter KJ, Balasubramanian A, Pulapaka AV, Chen ES, Brown SW, et al. Heterogeneity of lung function phenotypes in sarcoidosis: role of race and sex differences.

Ann Am Thorac Soc. (2023) 20:30–7. doi: 10.1513/AnnalsATS.202204-328OC

39. Abe S, Yamaguchi E, Makimura S, Okazaki N, Kunikane H, Kawakami Y. Association of HLA-DR with sarcoidosis. Correlation with clinical course. Chest. (1987) 92:488–90. doi: 10.1378/chest.92.3.488
40. Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of conventional transbronchial needle aspiration in sarcoidosis: a systematic review and meta-analysis. Respir Care. (2013) 58:683–93. doi: 10.4187/respcare.02101
41. Dhooria S, Sehgal IS, Gupta N, Bal A, Prasad KT, Aggarwal AN, et al. A randomized trial evaluating the effect of 10 versus 20 revolutions inside the lymph node on the diagnostic yield of EBUS-TBNA in subjects with sarcoidosis. Respiration. (2018) 96:464–71. doi: 10.1159/000490192
42. Rivera-Ortega P, Molina-Molina M. Interstitial lung diseases in developing countries. Ann Glob Health. (2019) 85:4. doi: 10.5334/aogh.2414
43. Iyer VN, Schroeder DR, Parker KO, Hyatt RE, Scanlon PD, Iyer VN, et al. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest. (2011) 139:878–86. doi: 10.1378/chest.10-0804
44. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. (2010) 4:367–88. doi: 10.1177/1753465810379801
45. Goobie GC, Ryerson CJ, Johannson KA, Schikowski E, Zou RH, Khalil N, et al. Neighborhood-level disadvantage impacts on patients with fibrotic interstitial lung disease. Am J Respir Crit Care Med. (2022) 205:459–67. doi: 10.1164/rccm.202109-2065OC
46. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. (2001) 345:340–50. doi: 10.1056/NEJM200108023450506
47. Zhao A, Unterman A, Abu Hussein N, Sharma P, Flint J, Yan X. Peripheral blood single-cell sequencing uncovers common and specific immune aberrations in fibrotic lung diseases. bioRxiv [Preprint]. (2023). doi: 10.1101/2023.09.20.558 301v1
48. Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki E-A, Antoniou K, Aidinis V. Commonalities between ARDS, pulmonary fibrosis and COVID- 19: the potential of autotaxin as a therapeutic target. Front Immunol. (2021) 12:687397. doi: 10.3389/fimmu.2021.687397
49. Ren L-L, Li X-J, Duan T-T, Li Z-H, Yang J-Z, Zhang Y-M, et al. Transforming growth factor-β signaling: from tissue fibrosis to therapeutic opportunities. Chem Biol Interact. (2023) 369:110289. doi: 10.1016/j.cbi.2022.110289
50. Unterman A, Zhao AY, Neumark N, Schupp JC, Ahangari F, Cosme Jr C, et al. Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis. medRxiv. (2023). doi: 10.1101/2023.04.29.23289296
51. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)–lung study. Am J Respir Crit Care Med. (2009) 180:407–14. doi: 10.1164/rccm.200812-1966OC
52. Borgerding M, Klus H. Analysis of complex mixtures–cigarette smoke. Exp Toxicol Pathol. (2005) 57:43–73. doi: 10.1016/j.etp.2005.05.010
53. Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of

Disease Study 2019. Lancet. (2020) 396:1223–49. doi: 10.1016/S0140-6736(20)30752-2

54. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. (1997) 349:1498–504. doi: 10.1016/S0140-6736(96)07492-2
55. Xiaochen D, Emmanuela G, Alan DL. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. (2022) 31:129. doi: 10.1136/tobaccocontrol-2021-056535
56. Kumar A, Cherian SV, Vassallo R, Eunhee SY Ryu JH. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest. (2018) 154:394–408. doi: 10.1016/j.chest.2017.11.023
57. Vassallo R, Ryu JH. Smoking-related interstitial lung diseases. Clin Chest Med.(2012) 33:165–78. doi: 10.1016/j.ccm.2011.11.004
58. Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. Am J Med. (1965) 39:369–404. doi: 10.1016/0002-9343(65)90206-8
59. Hellemons ME, Moor CC, von der Thüsen J, Rossius M, Odink A, Thorgersen LH, et al. Desquamative interstitial pneumonia: a systematic review of its features and outcomes. Eur Respir Rev. (2020) 29:190181. doi: 10.1183/16000617.0181-2019
60. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med. (1974) 291:755–8. doi: 10.1056/NEJM197410102911503
61. Johannson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, et al. Air pollution exposure is associated with lower lung function, but not changes in lung function, in patients with idiopathic pulmonary fibrosis. Chest. (2018) 154:119–25. doi: 10.1016/j.chest.2018.01.015
62. World Health Organization. Ambient (outdoor) Air Pollution. Geneva: WHO (2022). Johannson KA, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. (2014) 43:1124–31. doi: 10.1183/09031936.00122213
63. Johannson KA, Balmes JR, Collard HR. Air pollution exposure: a novel environmental risk factor for interstitial lung disease? Chest. (2015) 147:1161–7. doi: 10.1378/chest.14-1299
64. Conti S, Harari S, Caminati A, Zanobetti A, Schwartz JD, Bertazzi PA, et al. The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy. Eur Respir J. (2018) 51:1700397. doi: 10.1183/13993003.00397-2017
65. Singh S, Collins BF, Bairwa M, Joshi JM, Talwar D, Singh N, et al. Hypersensitivity pneumonitis and its correlation with ambient air pollution in urban India. Eur Respir J. (2019) 53:1801563. doi: 10.1183/13993003.01563-2018
66. Goobie GC, Nouraie M, Zhang Y, Kass DJ, Ryerson CJ, Carlsten C, et al. Air pollution and interstitial lung diseases: defining epigenomic effects. Am J Respir Crit Care Med. (2020) 202:1217–24. doi: 10.1164/rccm.202003-0836PP
67. Danielle A-O, Martin K. Interstitial lung disease: time to rethink the snapshot diagnosis? Thorax. (2016) 71:5. doi: 10.1136/thoraxjnl-2015-208148
68. n-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet P-Y, et al. Acute exacerbation of idiopathic pulmonary fibrosis:

outcome and prognostic factors. Respiration. (2012) 83:28–35. doi: 10.1159/000329891

69. Blanc PD, Annesi-Maesano I, Balmes JR, Cummings KJ, Fishwick D, Miedinger D, et al. The occupational burden of nonmalignant respiratory diseases. An official american thoracic society and european respiratory society statement. Am J Respir Crit Care Med. (2019) 199:1312–34. doi: 10.1164/rccm.201904-0717ST
70. Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global asbestos disaster. Int J Environ Res Public Health. (2018) 15:1000. doi: 10.3390/ijerph15051000
71. Cullinan P, Reid P. Pneumoconiosis. Prim Care Respir J. (2013) 22:249–doi: 10.4104/pcrj.2013.00055
72. Albert RK, Schwartz DA. Revealing the secrets of idiopathic pulmonary fibrosis.N Engl J Med. (2019) 380:94–6. doi: 10.1056/NEJMcibr1811639
73. Adegunsoye A, Newton CA, Oldham JM, Ley B, Lee CT, Linderholm AL, et al. Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts. Nat Commun. (2023) 14:1489. doi: 10.1038/s41467-023-37193-6
74. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult- onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. (2007) 104:7552–7. doi: 10.1073/pnas.0701009104
75. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. (2008) 45:654–6. doi: 10.1136/jmg.2008.057356
76. Diaz de. Leon A, Cronkhite JT, Katzenstein A-LA, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS ONE. (2010) 5:e10680. doi: 10.1371/journal.pone.0010680
77. García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. (2011) 105:1902–7. doi: 10.1016/j.rmed.2011.08.022
78. Cano-Garcia L, Manrique-Arija S, Urena I, Mena-Vazquez N, Ordonez- Canizares MC, Romero-Barco CM, et al. Telephone follow-up, standardized to the initiation of biologic therapy of patients with rheumatoid arthritis (RA) in a specific unit of biologic therapy. Pilot study. Ann Rheum Dis. (2016) 75 (Supplement 2):1300. doi: 10.1136/annrheumdis-2016-eular.1432
79. Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. (2017) 5:869–80. doi: 10.1016/S2213-2600(17)30387-9
80. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. (2013) 45:613–20. doi: 10.1038/ng.2609
81. Oldham JM, Ma S-F, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. (2015) 192:1475–82. doi: 10.1164/rccm.201505-1010OC.

HOW TO CITE: Abushan Khan*, Dr. Kaushal Kumar, Lifestyle Strategies for Symptom Relief and Disease Progression Control in Interstitial Lung Disease: A Comprehensive Review, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 9, 284-298 https://doi.org/10.5281/zenodo.17046299